share_log

20-F: FY2024 Annual Report

20-F: FY2024 Annual Report

20-F:2024財年年報
美股SEC公告 ·  09/27 04:42

Moomoo AI 已提取核心訊息

Alterity Therapeutics, a biotechnology company, has filed its annual report for the fiscal year ended June 30, 2024, with the United States Securities and Exchange Commission. The report does not include specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share. However, it does indicate that the company has complied with the SEC's reporting requirements over the past 12 months and is up to date with its electronic filings. The company's share structure is detailed, with 5,245,115,318 Ordinary Shares outstanding as of the end of the fiscal year. Alterity Therapeutics has also disclosed its employee count, which stands at 10 as of June 30, 2024, a slight decrease from 11 employees in 2023 and 12 in 2022. The workforce is primarily based in...Show More
Alterity Therapeutics, a biotechnology company, has filed its annual report for the fiscal year ended June 30, 2024, with the United States Securities and Exchange Commission. The report does not include specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share. However, it does indicate that the company has complied with the SEC's reporting requirements over the past 12 months and is up to date with its electronic filings. The company's share structure is detailed, with 5,245,115,318 Ordinary Shares outstanding as of the end of the fiscal year. Alterity Therapeutics has also disclosed its employee count, which stands at 10 as of June 30, 2024, a slight decrease from 11 employees in 2023 and 12 in 2022. The workforce is primarily based in Australia, with a smaller presence in the United States. The company's business development is not explicitly detailed in the report, but the maintenance of a directors' and officers' liability insurance policy and a policy for indemnification of directors and officers is noted, which could be indicative of the company's risk management strategies. The report does not provide explicit future plans or strategic initiatives.
生物技術公司Alterity Therapeutics已向美國證券交易委員會提交了截至2024年6月30日的財政年度年度報告。報告未包含特定的財務業績指標,如營業收入、營業利潤、淨利潤或每股攤薄收益。然而,報告表明公司在過去12個月內已符合SEC的報告要求,並按時提交了電子申報。報告詳細介紹了公司的股份結構,截至財政年度結束時,共有5,245,115,318股普通股在外流通。Alterity Therapeutics還披露了其員工人數,截至2024年6月30日爲10人,較2023年的11人和2022年的12人略有減少。員工主要駐紮在澳洲,在美國也有一小部分。報告未明確詳細列出公司的業務發展,但指出了維護董事和高管責任保險政策以及董事和高管賠償政策,這可能預示着公司的風險管理策略。報告未提供明確的未來計劃或戰略舉措。
生物技術公司Alterity Therapeutics已向美國證券交易委員會提交了截至2024年6月30日的財政年度年度報告。報告未包含特定的財務業績指標,如營業收入、營業利潤、淨利潤或每股攤薄收益。然而,報告表明公司在過去12個月內已符合SEC的報告要求,並按時提交了電子申報。報告詳細介紹了公司的股份結構,截至財政年度結束時,共有5,245,115,318股普通股在外流通。Alterity Therapeutics還披露了其員工人數,截至2024年6月30日爲10人,較2023年的11人和2022年的12人略有減少。員工主要駐紮在澳洲,在美國也有一小部分。報告未明確詳細列出公司的業務發展,但指出了維護董事和高管責任保險政策以及董事和高管賠償政策,這可能預示着公司的風險管理策略。報告未提供明確的未來計劃或戰略舉措。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息